Risk of interactions between daprodustat and other drugs

Although Daprodustat has obvious advantages in clinical application, as a small molecule drug metabolized by the CYP450 enzyme system, its risk of interaction with other drugs cannot be ignored, especially in patients with chronic kidney disease who take multiple basic medications.

In the metabolic pathway, daprostat mainly relies onCYP2C8 enzyme for decomposition and clearance, so any drug that affects CYP2C8 activity may change its concentration in the body. Co-administration with strong CYP2C8 inhibitors (such as gemfibrozil) will significantly increase the exposure of daprexostat, thereby increasing the risk of adverse reactions, so such combinations are expressly prohibited. When used concurrently with moderate CYP2C8 inhibitors (such as clopidogrel), plasma concentrations may also increase. At this time, the starting dose of daprostat needs to be halved. If the patient is already taking the lowest starting dose of 1 mg, hemoglobin levels need to be monitored more closely and the dose adjusted.

On the other hand,CYP2C8 inducers (such as rifampin) will accelerate the metabolism of daprostat, resulting in a decrease in drug exposure, thus affecting the efficacy. The combined use of such drugs may lead to poor control of anemia. Doctors usually increase the dose of daprostat appropriately based on the patient's hemoglobin monitoring results, or adjust the treatment strategy if necessary.

In addition toCYP2C8-related drugs, it is also common to combine iron, antihypertensive drugs, anticoagulants or diabetes drugs in clinical practice. Although no significant metabolic conflict has been found between daprostat and these drugs, doctors still need to pay attention to the potential risk of drug effects or adverse reactions. For example, when used together with anticoagulants, you should monitor whether there is an increased risk of bleeding, and when used together with antihypertensive drugs, you need to pay attention to blood pressure fluctuations.

Therefore, patients using daprostat must strictly follow their doctor's instructions and avoid changing or adding medications on their own. In clinical practice, doctors will closely monitor hemoglobin and iron metabolism indicators at the beginning of treatment and when adjusting drug regimens, and dynamically adjust the dosage based on test results and the risk of drug interactions.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat